The clinical consequences of an unverified allergy label are far larger than most patients and clinicians realize. When a penicillin allergy is documented, prescribers routinely abandon beta-lactam antibiotics, the workhorse class that includes penicillins, cephalosporins, and carbapenems, in favor of broader-spectrum alternatives such as fluoroquinolones or vancomycin. Those substitutes are less targeted, more expensive, and more toxic. Population-based cohort research has linked documented penicillin allergy to increased risks of methicillin-resistant Staphylococcus aureus and Clostridium difficile infection, and other studies have associated the label with longer hospital stays, higher healthcare costs, and elevated rates of surgical site infection when prophylactic antibiotics must be swapped for inferior options.

Immunologically, true penicillin allergy is an IgE-mediated or T-cell–mediated hypersensitivity to the beta-lactam ring or its side chains. IgE-mediated reactions can produce urticaria, angioedema, bronchospasm, and anaphylaxis, typically within minutes to hours of exposure. T-cell–mediated delayed reactions, including maculopapular exanthems and severe cutaneous adverse reactions such as Stevens-Johnson syndrome, emerge days after drug exposure. But the review emphasizes that most reported reactions are not immune-mediated at all. Common culprits include viral exanthems in children misattributed to the antibiotic, gastrointestinal intolerance, and side effects such as nausea that have nothing to do with allergy. Many patients also outgrow their childhood reactions over decades, yet the label persists indefinitely in the electronic health record.

Cross-reactivity data further weaken the case for reflexive avoidance. Systematic reviews and meta-analyses have quantified cross-reactivity between penicillins and cephalosporins at low rates, driven largely by shared side chains rather than the beta-lactam core itself. Cross-reactivity with carbapenems is even lower. This means that even patients with confirmed penicillin allergy can often tolerate carefully selected cephalosporins, and the blanket avoidance of entire antibiotic classes is scientifically unjustified in most cases.

The PEN-FAST clinical decision rule represents a major advance in identifying which patients can be safely and rapidly evaluated. Developed and validated by Trubiano and colleagues, the rule assigns points for five features: facial swelling, anaphylaxis, severe cutaneous adverse reactions, the timing of the reaction within one hour of drug exposure, and treatment required for the reaction. Low-risk patients, defined by low scores, can proceed directly to oral challenge without skin testing. The rule’s simplicity means it can be applied by nonallergy specialists, including hospitalists, pharmacists, and primary care clinicians, dramatically expanding the workforce capable of delabeling.

The PALACE randomized clinical trial provided the strongest evidence yet that streamlined evaluation is safe. In this multicenter trial, low-risk adults were randomized to direct oral penicillin challenge or to traditional skin testing followed by challenge. The direct challenge approach was noninferior to skin testing, with very low rates of adverse reactions in both arms. The finding upends the conventional assumption that skin testing must always precede oral exposure, and it removes a major logistical barrier, since skin testing requires trained personnel, specialized reagents, and multiple visits that many health systems cannot provide.

Delabeling programs have now been implemented at the level of entire hospitals with measurable results. The Penicillin Allergy Delabeling Program, a multicenter whole-of-hospital intervention, demonstrated that systematic assessment and removal of inaccurate labels changes prescribing patterns. Pharmacist-led programs in tertiary care hospitals have successfully delabeled large numbers of inpatients, and systematic reviews and meta-analyses confirm that interventions delivered by nonallergy specialists are effective in both adult and pediatric populations. Economic evaluations suggest that penicillin allergy testing is cost-saving, offsetting the expense of evaluation through reduced use of broader-spectrum agents and fewer complications.

Electronic health record tools are emerging as a scalable frontier for delabeling. Clinical decision support systems, including an Allergy Fact Checker evaluated in a mixed-methods study, can flag inconsistent or low-risk allergy labels at the point of care and prompt clinicians to reassess them. These digital tools promise to embed delabeling into routine workflows rather than relying on opportunistic conversations, and they align with guidance from the American Academy of Allergy, Asthma and Immunology that penicillin allergy evaluation should be performed proactively rather than waiting for patients to request it.

The review’s practical recommendations center on integrating delabeling into antimicrobial stewardship programs, which are already mandated in most hospitals under guidelines from the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Stewardship teams can incorporate allergy assessment into admission workflows, prioritize patients facing imminent surgical procedures or serious infections where beta-lactams are first-line therapy, and use PEN-FAST to stratify risk before referral. The authors frame the evidence-practice gap as the central remaining challenge: the science is settled enough to act, but health systems have been slow to operationalize it.

For patients, the message is equally direct. A penicillin allergy label recorded decades ago, often in childhood, deserves reevaluation rather than lifelong deference. Removing an inaccurate label restores access to safer, narrower, and cheaper antibiotics, reduces the risk of resistant infections, and improves surgical prophylaxis. As delabeling evidence accumulates and digital tools mature, the review suggests that the era of treating an unverified allergy as a permanent diagnosis is coming to an end, and that closing this gap may be one of the highest-yield interventions available to modern antimicrobial stewardship.

Subject of Research: Penicillin allergy delabeling as an antimicrobial stewardship strategy

Article Title: Penicillin Allergy Delabeling: Bridging the Evidence-Practice Gap in Antimicrobial Stewardship

Article References: Raja, M., Patel, K., Krish, P., & Azam, Z. (2026). Penicillin Allergy Delabeling: Bridging the Evidence-Practice Gap in Antimicrobial Stewardship. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10793-w

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10793-w

Keywords: penicillin allergy, allergy delabeling, antimicrobial stewardship, beta-lactam antibiotics, PEN-FAST, PALACE trial, oral challenge, antibiotic resistance, clinical decision rule, hospital medicine, Penicillin, Allergy

The research team, led by investigators from Zhongda Hospital and the Jiangsu Provincial Key Laboratory of Critical Care Medicine at Southeast University in Nanjing, China, scoured four major databases—PubMed, EMBASE, Web of Science, and the Cochrane Library—for randomized controlled trials published between January 2000 and July 2025. After screening 2,516 records and reviewing 191 full-text articles, they identified 25 eligible randomized trials encompassing 9,915 critically ill adults. The trials compared three intravenous administration strategies: continuous infusion, defined as an uninterrupted 24-hour drip typically preceded by a loading dose; extended infusion, in which each dose is delivered over three to four hours, roughly 40 to 50 percent of the dosing interval; and intermittent infusion, the conventional approach in which each dose is pushed or infused over an hour or less. Strikingly, despite decades of clinical experience with both prolonged strategies, not a single trial directly pitted continuous infusion against extended infusion in a head-to-head comparison.

The pharmacological rationale behind prolonged infusion is elegant. Beta-lactams are time-dependent bactericidal agents: their killing power depends on the percentage of time that free, unbound drug concentrations remain above the pathogen’s MIC, a metric pharmacologists abbreviate as %fT greater than MIC. Conventional intermittent dosing produces high peak concentrations, but those levels plummet between doses, and in septic patients—whose fluid shifts, organ dysfunction, and augmented renal clearance dramatically alter drug distribution and elimination—concentrations can dip into subtherapeutic territory for dangerous stretches. Prolonging the infusion, whether continuously or over several hours per dose, keeps drug levels above the killing threshold for a greater fraction of the dosing interval, suppressing bacterial regrowth and improving the odds of infection control.

Yet the two prolonged strategies differ in ways that matter enormously at the bedside. Continuous infusion typically demands a dedicated intravenous line, because beta-lactams can be chemically incompatible with other continuously infused drugs, forcing clinicians to reserve a lumen solely for the antibiotic. Many beta-lactams—meropenem being the notorious example—are chemically unstable at room temperature over 24 hours, requiring frequent replacement of infusion bags and driving up nursing workload, catheter utilization, and costs. Extended infusion, by contrast, piggybacks on existing central or peripheral venous access, preserves conventional dosing intervals, and frees the line between doses for other medications. These practical considerations explain why extended infusion has been adopted more widely in intensive care units worldwide, even as pharmacodynamic theory favored the steadier exposure of continuous infusion.

The new analysis, registered prospectively in PROSPERO and conducted according to PRISMA guidelines for network meta-analysis, used Markov chain Monte Carlo methods in the R statistical environment to weave together direct and indirect evidence across the trial network. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the Cochrane tool, with publication bias evaluated through funnel plots and Egger’s test. Certainty of evidence was graded with the GRADE framework adapted for network meta-analysis, and a trial sequential analysis was performed to gauge whether the accumulated evidence was sufficient to rule out random error.

The headline findings are nuanced. Against intermittent infusion, continuous infusion was associated with a statistically significant reduction in all-cause mortality, with a relative risk of 0.85 and a 95 percent confidence interval of 0.66 to 0.98, rated as moderate certainty evidence. In absolute terms, that translates to roughly 39 fewer deaths per 1,000 patients. Extended infusion also showed a mortality benefit relative to intermittent dosing—a relative risk of 0.80—but with a confidence interval spanning 0.60 to 1.10, the effect was statistically uncertain and carried only low certainty. Both prolonged strategies significantly improved clinical cure rates compared with intermittent infusion: continuous infusion achieved a relative risk of 1.10 (95 percent CI 1.03 to 1.20), while extended infusion posted a more pronounced relative risk of 1.28 (95 percent CI 1.07 to 1.55), both at moderate certainty. Neither strategy, however, demonstrated a clear effect on intensive care unit length of stay, with wide confidence intervals straddling the null for both comparisons.

The pivotal question—continuous versus extended infusion—could only be answered indirectly, since no direct trials exist. The network meta-analysis found no statistically significant differences between the two strategies in mortality (relative risk 1.06, 95 percent CI 0.73 to 1.44), clinical cure (relative risk 0.86, 95 percent CI 0.70 to 1.05), or ICU length of stay (mean difference 0.86 days, 95 percent CI -3.32 to 4.54). But the Bayesian posterior probability analysis added a provocative twist: there was a 93.2 percent probability that extended infusion achieves higher clinical cure rates than continuous infusion, and a 63.7 percent probability that extended infusion is superior for reducing mortality. The authors suggest the stronger cure signal may reflect more reliable drug exposure with extended infusion, particularly for carbapenems whose 24-hour stability is questionable—degradation during prolonged room-temperature infusion could silently undermine continuous regimens.

The analysis confronted several methodological challenges head-on. The massive BLING III trial, published in JAMA in 2024, contributed approximately 70 percent of the total study population, raising concerns that a single study could dominate the pooled estimates. A prespecified leave-one-out sensitivity analysis excluding BLING III nonetheless preserved the core findings: continuous infusion retained its mortality advantage over intermittent infusion (relative risk 0.78, 95 percent credible interval 0.60 to 0.96) and its clinical cure benefit (relative risk 1.09, 95 percent credible interval 1.01 to 1.23), while the indirect continuous-versus-extended comparisons remained nonsignificant. Trial sequential analysis confirmed that the cumulative evidence for the continuous-versus-intermittent mortality comparison crossed the required information size and statistical significance boundary, whereas the extended-versus-intermittent mortality estimate never reached conventional significance, underscoring the lingering uncertainty around that strategy’s survival effect.

The authors are careful to frame their conclusions with appropriate humility. Most included trials were open-label, exposing patients and clinicians to performance bias, which forced downgrades in certainty of evidence. Outcome definitions varied considerably—mortality was captured at timepoints ranging from ICU discharge to 90 days, and clinical cure was defined differently across studies. Pharmacokinetic heterogeneity among critically ill patients, driven by renal replacement therapy, albumin levels, and dynamic organ function, may produce interindividual variation in drug exposure that dwarfs any difference between the two prolonged strategies. Moreover, few trials employed systematic therapeutic drug monitoring, leaving actual drug concentrations unknown and potentially masking true differences between regimens.

Nevertheless, the practical implications are hard to ignore. If extended infusion delivers outcomes statistically indistinguishable from continuous infusion—while sparing patients dedicated lines, extra infusion pumps, and hospitals the associated costs and nursing burden—then the simpler strategy may be sufficient for routine critical care. The 93.2 percent posterior probability favoring extended infusion for clinical cure, though hypothesis-generating rather than definitive, gives intensive care clinicians a data-driven nudge toward a regimen that is easier to implement at scale. What the field now desperately needs is a large, adequately powered randomized trial directly comparing continuous infusion with extended infusion, ideally incorporating therapeutic drug monitoring to illuminate whether concentration control, rather than infusion duration per se, drives the outcomes that matter. Until such a trial arrives, this analysis suggests that the ICU’s antibiotic drip debate may be closer to resolution than anyone expected—and that the answer may favor the pragmatic option already sitting at most patients’ bedsides.

Subject of Research: Comparison of continuous, extended, and intermittent beta-lactam antibiotic infusion strategies in critically ill adults

Article Title: β-lactam infusion strategies in critical illness: is continuous superior to extended infusion? A systematic review and network meta-analysis

Article References: Peng, F., Tang, Z., Hu, Z., Zhou, X., Kang, L., Chang, W., Sun, Q., Xie, J., Qiu, H., & Yang, Y. (2026). β-lactam infusion strategies in critical illness: is continuous superior to extended infusion? A systematic review and network meta-analysis. Frontiers in Epidemiology, 6, Article 1883520. https://doi.org/10.3389/fepid.2026.1883520

Image Credits: AI Generated

DOI: 10.3389/fepid.2026.1883520

Keywords: beta-lactam antibiotics, sepsis, intensive care, continuous infusion, extended infusion, network meta-analysis, pharmacokinetics, clinical cure, mortality, critical care, antibiotic dosing, BLING III trial

The research, published in PLOS Genetics by Jake Colautti, Alexander C. Anderson, Wyatt P. K. Clark, and Lindsey S. Marmont, focuses on a long-standing puzzle in bacterial cell biology: how dividing cells switch on the synthesis of septal peptidoglycan, the new cell wall material that must be forged at exactly the right place and time as a bacterium splits in two. In rod-shaped bacteria such as P. aeruginosa and the better-studied Escherichia coli, this task falls to a pair of enzymes known as FtsW and FtsI. FtsW is a member of the SEDS family of membrane proteins, while FtsI is a class B penicillin-binding protein, and together the FtsWI complex carries out the essential work of polymerizing and cross-linking the peptidoglycan strands at the division septum. Without properly regulated FtsWI activity, the cell cannot complete division and dies.

For years, microbiologists have believed that FtsWI sits in a dormant state until it receives an activating signal from the rest of the divisome, the elaborate protein assembly that assembles at the future site of division. The accepted model describes an allosteric cascade: the late-arriving divisome protein FtsN, considered the final trigger of cytokinesis, transmits its signal through the FtsQ, FtsL, and FtsB proteins, which form a complex known as FtsQLB, and this complex in turn stimulates FtsWI to begin building the septum. Yet the molecular details of this handoff have remained murky, and the picture appears to differ from one bacterial species to another. The new study set out to clarify how this regulatory cascade works in P. aeruginosa, an organism that is both a formidable pathogen and, until recently, less genetically tractable than E. coli.

The team’s strategy exploited a key genetic feature: the gene encoding FtsN, while essential, can be studied through conditional essentiality, meaning the researchers could remove it and then search for mutations elsewhere in the genome that allow cells to survive without it. This approach, often called a suppressor screen, is a powerful way to identify the components of a regulatory pathway. If a mutation in another gene can compensate for the loss of FtsN, that gene very likely participates in the same process. When the researchers deleted ftsN and looked for survivors, they found them, and the compensating mutations mapped to a specific region of the ftsI gene encoding the non-enzymatic pedestal domain of the FtsI protein.

The pedestal domain is a region of FtsI that sits outside the enzyme’s catalytic machinery, and it had not previously been considered a major control point for septal cell wall synthesis. The substitutions the team identified did more than merely rescue the loss of FtsN. The mutant cells also suppressed the toxic effects of activation-defective ftsL alleles, versions of FtsL that dominantly disrupt division when present, and they shortened cell length even in an otherwise normal genetic background. Together, these observations indicate that the pedestal mutations change how FtsWI is regulated, allowing the enzyme complex to escape its dependence on stimulation by both FtsN and the FtsQLB complex. In effect, the mutations rewire the switch that normally holds septal peptidoglycan synthesis in check until the divisome is fully assembled.

To understand where these substitutions sit in three-dimensional space, the researchers mapped them onto the recently determined structure of the P. aeruginosa FtsQLBWI complex. The result was striking: rather than clustering at a single site, the mutations grouped onto distinct surfaces of the pedestal domain. Some variants localized to the interface where FtsI contacts FtsL, consistent with the idea that the FtsQLB complex physically transmits its activating signal to FtsWI through this contact. Others sat on the opposite face of the pedestal, suggesting that this surface engages a different regulatory input, possibly FtsN itself or another partner in the divisome. The pedestal domain, in other words, behaves as an integration point where multiple signals converge to control the timing and magnitude of septal cell wall construction.

The most consequential twist came from a clinical observation. Several of the pedestal substitutions identified in the study had previously been found in clinical isolates of P. aeruginosa showing increased resistance to aztreonam, a monocyclic β-lactam antibiotic that is one of the few options remaining against multidrug-resistant Gram-negative infections. That overlap prompted the team to ask a direct question: do these cell-division regulatory mutations change how susceptible the bacterium is to β-lactam antibiotics, which kill cells by sabotaging cell wall synthesis?

The answer depended on which surface of the pedestal domain was altered. Variants affecting the FtsI-FtsL interface modestly reduced the bacterium’s susceptibility to multiple β-lactam antibiotics, nudging the minimum inhibitory concentrations upward. Far more dramatic was the effect of a variant on the opposite face of the pedestal: this mutation produced striking hypersusceptibility to the same drugs, but only when FtsN was present. In other words, a single amino acid change in a non-enzymatic region of a cell wall synthase could either harden the pathogen against β-lactams or render it exquisitely vulnerable, depending on its position and on the presence of the divisome’s triggering protein.

These results carry two significant implications. First, they establish the FtsI pedestal domain as a central regulatory hub for FtsWI, resolving long-standing uncertainty about how the FtsN-to-FtsQLB-to-FtsWI cascade is wired in P. aeruginosa and demonstrating that the non-enzymatic architecture of a cell wall synthase can govern its activity. Second, and more urgently, they reveal a previously unrecognized relationship between divisome regulation and β-lactam susceptibility. Antibiotic resistance in P. aeruginosa is usually attributed to enzymatic drug destruction, efflux pumps, and reduced permeability, but this work shows that subtle alterations in the regulation of septal peptidoglycan synthesis can also shift the balance between life and death in the presence of β-lactams, and that such alterations already exist in clinical isolates.

The study also suggests new directions for drug discovery and surveillance. If the pedestal domain integrates the signals that unleash septal cell wall synthesis, then molecules that lock the domain into a hypersusceptible state, mimicking the effect of the sensitizing mutation, could potentially restore the potency of β-lactams against resistant strains. Conversely, sequencing efforts that monitor pedestal-domain residues in clinical P. aeruginosa populations might provide early warning of emerging β-lactam tolerance that conventional resistance mechanisms would miss. As the authors note, the work highlights the potential relevance of divisome regulation to β-lactam resistance in the clinic, transforming a fundamental question about bacterial cell biology into a matter of direct medical consequence.

Subject of Research: Regulation of septal peptidoglycan synthesis and its effect on β-lactam antibiotic susceptibility in Pseudomonas aeruginosa

Article Title: Altered regulation of septal peptidoglycan synthesis modulates β-lactam susceptibility in Pseudomonas aeruginosa

Article References: Colautti, J., Anderson, A. C., Clark, W. P. K., & Marmont, L. S. (2026). Altered regulation of septal peptidoglycan synthesis modulates β-lactam susceptibility in Pseudomonas aeruginosa. PLOS Genetics, 22(9), e1012319. https://doi.org/10.1371/journal.pgen.1012319

Image Credits: AI Generated

DOI: 10.1371/journal.pgen.1012319

Keywords: Pseudomonas aeruginosa, cell division, peptidoglycan synthesis, FtsI, FtsN, FtsQLB complex, divisome, beta-lactam antibiotics, aztreonam, antibiotic resistance, SEDS-bPBP synthase, pedestal domain

The story began with an elective abdominal operation in a patient whose medical history was already extraordinarily complex. She carried a diagnosis of VACTERL association, a congenital syndrome involving vertebral defects, anal atresia, cardiac malformations, tracheoesophageal fistula, renal anomalies, and limb abnormalities, and she had undergone multiple reconstructive surgeries as well as treatment for advanced gynecologic cancer. The planned exploratory laparotomy included removal of both ovaries and fallopian tubes, lysis of adhesions, repair of a small bowel leak, and placement of a temporary ureteral stent. For eight days her recovery proceeded uneventfully. Then, during a failed attempt to place a nasogastric tube for a suspected ileus, she suffered a pulseless electrical activity arrest. After eight minutes of cardiopulmonary resuscitation, her heartbeat returned, she was intubated and sedated, and surgeons re-entering her abdomen found frank pus. Septic shock was diagnosed as the likely cause of the arrest, and broad-spectrum antibiotics were started.

The neurological trouble surfaced on postoperative day 9, when abnormal movements concerning for seizure appeared during an attempt to wean her sedation. Neurologists ordered continuous electroencephalography, which recorded unreactive theta slowing consistent with severe encephalopathy, along with myoclonic movements that occurred without any evolving electrographic seizure activity. The official interpretation described findings consistent with postanoxic myoclonus, a phenomenon long regarded as an ominous sign after cardiac arrest. On examination the patient was comatose, her pupillary reflexes were the only preserved brainstem findings, and she exhibited severe stimulus-induced generalized myoclonus. Laboratory markers told a mixed story: elevated liver enzymes and troponin suggested ongoing hypoperfusion, but neuron-specific enolase, a blood biomarker of neuronal injury, remained reassuringly low at 16, 14, and 15 nanograms per milliliter over the first three days after the arrest. Head computed tomography showed nothing abnormal, and magnetic resonance imaging was scheduled three to five days after the arrest in keeping with neuroprognostication guidelines.

What followed was a cascade of findings that failed to converge on the grim prognosis the early exam had implied. Bacteremia from Enterobacter was confirmed on day 10, prompting broader antibiotics. Brain MRI on day 11, three days after the arrest, revealed no cerebral ischemia at all, an outcome that directly contradicted the expected signature of severe hypoxic-ischemic injury. By day 13, nurses were reporting violent stimulus-induced myoclonus accompanied by autonomic changes that demanded repeated midazolam boluses every four hours, and her mental status did not improve even after propofol sedation was withdrawn. When neurology was reconsulted on day 15, the team recognized that none of the highly reliable predictors of poor outcome had actually been met, raising the possibility that a reversible metabolic or iatrogenic process was obscuring the true picture. Laboratory review then uncovered worsening acute kidney injury, a pivotal clue.

A repeat EEG changed the diagnostic landscape. This time it captured centrally predominant spikes time-locked to the clinical myoclonic jerks, a pattern the consulting team interpreted as cortical myoclonus with potential epileptogenicity, in contrast to the earlier recording that had suggested a subcortical origin without cortical spikes. Repeat MRI remained unchanged, deepening the puzzle. The case report uses this evolution to highlight a fundamental problem in post-arrest neurology: myoclonus can arise from the cortex or the subcortex, and the two are notoriously difficult to disentangle. Cortical myoclonus is classically associated with single midline or parasagittal EEG spikes against a continuous background, thought to reflect bilateral motor strip involvement transmitted through the corpus callosum. Subcortical posthypoxic myoclonus, by contrast, has been conceptualized as reticular reflex myoclonus, a stimulus-sensitive phenomenon arising from the medulla oblongata. In practice, EEG findings in subcortical myoclonus may be absent or nonspecific, movement artifacts contaminate recordings, electromyography leads that would help localize the jerk are often not used, and no clinical examination can reliably separate the two categories. Recent studies have even reported similar rates of favorable outcomes between the groups, eroding confidence in the dichotomy itself.

The report also addresses the question hanging over every such case: does postanoxic myoclonus doom a patient? Historically the answer was assumed to be yes, but contemporary evidence cautions strongly against relying on myoclonus, especially within the first 48 to 72 hours after return of spontaneous circulation, to guide irreversible decisions. Early motor findings can be distorted by sedatives, metabolic derangements, and drug-induced encephalopathy, and current guidelines explicitly warn against premature prognostication, urge clinicians to exclude modifiable factors, and recommend waiting at least 72 hours before using EEG findings prognostically. Importantly, the authors note that the vertex spike-wave discharges synchronized with the patient’s jerks have been described in the literature as a characteristic EEG phenotype of Lance-Adams syndrome, a chronic and typically survivable form of posthypoxic myoclonus. Recognizing that pattern earlier, they suggest, might have reframed the entire prognostic conversation.

That reframing opened the door to the case’s most consequential insight. Among the differential diagnoses was toxic myoclonus, and the team noted that the patient’s antibiotics had recently been broadened to cefepime, a fourth-generation cephalosporin with a well-documented neurological footprint. Beta-lactam antibiotics can induce encephalopathy by antagonizing GABA-A receptors, the brain’s principal inhibitory signaling system, producing cortical hyperexcitability that manifests as myoclonus and seizures; the full mechanism of the accompanying encephalopathy remains incompletely understood. The randomized ACORN trial further strengthened the suspicion, having demonstrated greater neurological dysfunction among hospitalized adults treated with cefepime than with piperacillin-tazobactam. Critically, the patient had possessed none of the recognized risk factors for cefepime neurotoxicity when the drug was first chosen, including advanced age, renal impairment, or prolonged high-dose therapy. Only as her kidney function deteriorated did the drug’s accumulation become a credible threat, a vivid reminder that critically ill patients have rapidly shifting metabolic states that demand continual reassessment of neuroactive prescriptions.

On day 16, cefepime was discontinued and replaced with metronidazole and piperacillin-tazobactam, while valproate was initiated for symptomatic myoclonus control based on literature supporting its use in posthypoxic cortical reflex myoclonus. The response was striking. By day 17, brainstem reflexes had returned. By day 20, she opened her eyes to voice, and over the following days she progressed to full alertness and consistent command-following, although stimulus-induced myoclonus stubbornly persisted. That persistence was diagnostically decisive: it supported a final diagnosis of Lance-Adams syndrome, likely layered with a toxic-metabolic overlay of cefepime-induced neurotoxicity in the setting of acute kidney injury, rather than cefepime toxicity alone. The chronic myoclonus continued to obstruct rehabilitation, and levetiracetam restarted alongside up-titrated valproate, a commonly reported first-line strategy, produced no benefit. Clonazepam was eventually added. Her mentation, however, kept improving, and she was discharged to a rehabilitation facility awake, communicative, and bearing a diagnosis that carries a typically favorable neurological outlook rather than the devastating prognosis her first days in the ICU had suggested.

The lessons the authors distill reach well beyond this single bedside. Clinical myoclonus alone, they argue, should never be treated as a definitive marker of severe anoxic brain injury, even though myoclonic status epilepticus with truly malignant EEG patterns remains a poor prognostic sign; neuroprognostication must instead weave together evolving EEG findings, examination, neuroimaging, and evoked potentials while actively hunting for modifiable contributors such as antibiotic-associated encephalopathy. Cefepime-induced neurotoxicity, they emphasize, can worsen mental status and provoke myoclonus and seizures, and it is exceptionally easy to miss in patients who already have neurological impairment, because every new abnormality gets attributed to the original injury. And Lance-Adams syndrome, though rare, should stand in every clinician’s mind as the favorable exception among postanoxic movement disorders. For a field in which prognostic statements can drive decisions about withdrawal of life-sustaining therapy, the case is a powerful demonstration that diagnostic clarity, patience, and a willingness to question early assumptions can quite literally change the predicted future of a patient who wakes up against the odds.

Subject of Research: Neuroprognostication after cardiac arrest complicated by postanoxic myoclonus and antibiotic-induced neurotoxicity

Article Title: Neurotoxicity in Neuroprognostication: The Importance of Differential Diagnostic Clarity

Article References: Tocco, E., Gruccio, P., Davidow, J., & Graziano, A. (2026). Neurotoxicity in Neuroprognostication: The Importance of Differential Diagnostic Clarity. Neurocritical Care. https://doi.org/10.1007/s12028-026-02654-5

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02654-5

Keywords: neuroprognostication, cardiac arrest, postanoxic myoclonus, Lance-Adams syndrome, cefepime neurotoxicity, electroencephalography, encephalopathy, septic shock, myoclonus, neurocritical care, beta-lactam antibiotics, GABA-A receptors

The heart of the technology is deceptively small: spherical nanoparticles roughly 30 nanometers across, each built around a core of iron oxide wrapped in a protective silica shell. This architecture gives the particles two crucial properties at once. The iron oxide core makes them strongly magnetic, allowing them to be maneuvered and concentrated within a sample without the lengthy centrifugation steps that conventional immunoassays demand, while the silica shell provides a chemically stable surface onto which the researchers attach thousands of molecular structures that mimic the antigenic determinants of beta-lactam antibiotics. Ezequiel Pérez-Inestrosa, Professor of Organic Chemistry at the University of Malaga and one of the study’s authors, describes each particle as acting ‘like a tiny magnet covered with thousands of molecular hooks.’ If a patient’s blood contains IgE antibodies responsible for the allergy, those antibodies are captured far more readily than with existing methods.

The significance of that capture efficiency becomes clear when the immunology of drug allergy is considered. IgE antibodies are extraordinarily scarce in the bloodstream, and the allergic response to penicillins is directed against haptens, small chemical fragments that only become immunologically visible when they are covalently bound to carrier proteins in the body. Recreating these hapten-carrier complexes faithfully on a solid support is a formidable synthetic chemistry challenge, and it is precisely where the Malaga team’s organic chemistry expertise proves decisive. By presenting a dense, well-defined array of antibiotic-derived structures on the nanoparticle surface, the platform maximizes the probability that even low-abundance, clinically relevant IgE molecules will bind, and the magnetic separation then allows those bound antibodies to be isolated and measured cleanly against a low background of noise.

Performance in the laboratory translated directly into diagnostic accuracy. In the study, the researchers analyzed blood samples from nearly one hundred people: 50 patients with confirmed amoxicillin allergy and 44 individuals who tolerated these antibiotics without incident. The system detected virtually all true cases of allergy while substantially reducing both false negatives and false positives, according to María José Torres, Professor of Medicine and one of the study’s lead researchers. The platform was benchmarked against two established techniques, ImmunoCAP, the most widely used commercial test, and the conventional radioallergosorbent test known as RAST. The gap in sensitivity, particularly for amoxicillin, was stark. Where the nanoparticle platform flagged 98 percent of confirmed allergic patients, ImmunoCAP managed only around 17 percent, a shortfall that means the majority of genuinely allergic individuals have historically received negative results that offer false reassurance.

The stakes of getting these diagnoses right are far higher than they might first appear. Penicillin allergy is dramatically overdiagnosed. Although between 8 and 25 percent of the population report being allergic to these antibiotics, only between 1 and 10 percent actually are. That gap between perception and reality leaves millions of people carrying an incorrect label in their medical records, and the consequences cascade through their subsequent care. Patients mislabeled as penicillin-allergic are treated with alternative drugs that are generally less effective and more toxic, and the substitution contributes to the emergence of bacterial resistance, one of the most pressing threats in modern medicine. ‘This incorrect label leads to the use of alternative drugs that are generally less effective, more toxic and contribute to the emergence of bacterial resistance,’ Pérez-Inestrosa explains. He stresses that identifying these cases safely would make it possible to remove thousands of incorrect diagnoses that currently shape and constrain patients’ treatment.

Beyond accuracy, the new platform promises to make the diagnostic journey itself safer and simpler. The definitive test for drug allergy has long been the drug provocation test, in which the patient is deliberately given the suspected medication under close medical supervision. It is informative, but it carries genuine risks, including the possibility of triggering a severe systemic reaction, and it requires specialist settings and considerable time. The nanoparticle-based assay, by contrast, can be performed rapidly in the laboratory on a simple blood sample, without exposing the patient to the drug at all and without the lengthy centrifugation procedures that slow down conventional workflows. A reliable in vitro alternative of this kind could allow clinicians to triage patients efficiently, reserving provocation testing only for cases where it is truly necessary.

The study is also a showcase for collaborative, translational science. Alongside the University of Malaga’s Department of Organic Chemistry, where Yolanda Vida and María I. Montañez serve as the study’s lead authors, the work drew on the IBIMA BIONAD Platform, the Inflammatory Diseases Network (REI) and the Regional University Hospital of Malaga, combining synthetic chemistry, materials science, immunology and clinical allergy expertise in a single program. That breadth matters, because a diagnostic technology that lives or dies on the precision of surface chemistry must ultimately prove itself against the messy, variable reality of patient sera, and few single laboratories possess the full range of skills needed to close that loop.

The implications, if the technology survives the scrutiny that now follows, extend beyond the penicillins. Beta-lactams are the world’s most prescribed class of antibiotics, and reliable, rapid allergy diagnosis would unlock first-line therapy for the vast majority of people currently denied it. There are also immediate operational benefits: shorter laboratory turnaround, reduced reliance on radioisotope-based legacy assays such as RAST, and the potential for standardization across centers because the magnetic separation is straightforward to automate. The authors themselves, however, are careful about the pace of translation. In light of their findings, they emphasize the need for further, larger multicentre studies and formal clinical validation before the platform can be introduced into hospitals and used routinely, a prudent stance given that diagnostic tests must perform consistently across diverse populations and instrumentation.

Still, the trajectory of this work is a reminder of how materials science quietly reshapes clinical medicine. Thirty-nanometer spheres of iron oxide and silica, decorated with molecular hooks synthesized by organic chemists, have turned a notoriously unreliable diagnostic corner into something that approaches certainty. For the millions of patients whose misplaced allergy label steers them toward inferior antibiotics, and for the clinicians trying to reconcile a 98 percent sensitivity figure with the 17 percent of the status quo, that tiny magnetic scaffold may prove to be one of the most consequential pieces of chemistry in the allergy clinic in years. The University of Malaga team’s findings, published in Materials Today Bio, mark the point at which magnetic nanoparticles moved from the bench toward a clinically relevant role in the diagnosis of beta-lactam allergy.

Subject of Research: Magnetic nanoparticle-based in vitro diagnosis of allergy to beta-lactam antibiotics such as amoxicillin and other penicillins

Article Title: Uma scientists develop a new technology that improves the diagnosis of allergy to antibiotics such as amoxicillin and other penicillins

Article References: Uma scientists develop a new technology that improves the diagnosis of allergy to antibiotics such as amoxicillin and other penicillins. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: magnetic nanoparticles, penicillin allergy, amoxicillin, beta-lactam antibiotics, IgE antibodies, in vitro diagnostics, ImmunoCAP, drug provocation test, antibiotic resistance, University of Malaga, Materials Today Bio, allergy diagnosis